A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Trial Profile

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301)

Discontinued
Phase of Trial: Phase III

Latest Information Update: 01 Aug 2018

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms Keynote-252 / ECHO-301
  • Sponsors Incyte Corporation; Merck Sharp & Dohme
  • Most Recent Events

    • 05 Jun 2018 Results of final analysis for progression free survival and interim analysis for overall survival presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 25 Apr 2018 According to an Incyte Corporation media release, data from this trial will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) annual meeting.
    • 06 Apr 2018 According to an Incyte Corporation media release, data from this study will be analyzed and submitted for presentation at an upcoming scientific congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top